Johnson and Johnson just lost a big one with its failed pain patch. It failed so badly that it killed someone. Everyone is trying to find new drugs to fill the void left by celebrex and related failures. This is big news and too bad for the company (and investors)

 

Submitted: Jun 20, 2007    Views: 227    Comments: 2    Likes: 8   


View Article: http://www.nytimes.com/2007/06/20/business/20drug.html


Related Articles:



8

Email this story Email to someone | Print Story Print Content | Add to reading list

Comments Received:

jsoc

Patches can be tricky- regarding delivery rates, etc.
Duragesic is a good med, and generally works really well.
I would not expect this to cause any major problems for JNJ.

Posted: Jun 20, 2007

JRodgers

It is going to be very difficult for the US drug manufacturers (and non-US drug manufacturers in the US) going forward after the Cox-2 debacle. The FDA will be clamping down and won't be taking any more chances with anything. The nixed Sanofi's Accomplia last week for a link to suicide.

Posted: Jun 20, 2007



Add Your Comments:

Your Name:

Spam protection control:


Financial products of all nature bear inherent risks and this website is not a financial advisory service; it is a forum for users to share and to compare notes and observations on financial publications. The website provides, free of charge, the technical and logistical apparatus and the medium for users to share and to publish financial information and to comment on publications. As such, the website’s operator can not and does not take responsibility for information, observations or opinions of any sort or nature provided by third parties with whom it is not affiliated who use the website to publish, to comment or as a means of solicitation. Users are specifically warned against following any advice related to specific instruments, including, but not limited to, equity securities, that may be provided by other users directly on this site or on web pages to which other users have provided links on this site. BestCashCow.com can not and does not check or verify the qualifications and credentials of users who publish or comment on this site or on linked pages. Users should seek personalized advice from qualified professionals regarding all personal financial issues and evaluate the risks and applicability to their own circumstances of each financial product discussed regardless of who the publisher is or purports to be. Should you, through your use of this site, identify an individual or organization purporting to offer personalized advice, you bear all responsibility to ensure that the individual or organization has the qualifications that they may represent on the website, and that their advice is appropriate for your circumstances. On certain webpages, BestCashCow.com provides information related to rates on US-based savings accounts, CDs, short-term government bonds, and other US cash equivalent securities, also free of charge to internet users for their independent use. The accuracy of this information is not guaranteed, and the information, like all other information on this website, should not be construed to provide investment advice, nor to endorse a financial product of any sort.

© 2007 BestCashCow.com, LLC. All Rights Reserved. Terms under which this service is provided to you. Privacy Policy.